291 related articles for article (PubMed ID: 33872943)
1. Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).
Ito S; Asahina H; Honjo O; Tanaka H; Honda R; Oizumi S; Nakamura K; Takamura K; Hommura F; Kawai Y; Ito K; Sukoh N; Yokoo K; Morita R; Harada T; Takashina T; Goda T; Dosaka-Akita H; Isobe H;
Lung Cancer; 2021 Jun; 156():12-19. PubMed ID: 33872943
[TBL] [Abstract][Full Text] [Related]
2. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.
Bilger G; Girard N; Doubre H; Levra MG; Giroux-Leprieur E; Giraud F; Decroisette C; Carton M; Massiani MA
Cancer Immunol Immunother; 2022 Jul; 71(7):1719-1731. PubMed ID: 34821950
[TBL] [Abstract][Full Text] [Related]
4. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
Watanabe H; Kubo T; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):762-765. PubMed ID: 31090906
[TBL] [Abstract][Full Text] [Related]
5. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
Torasawa M; Yoshida T; Takeyasu Y; Shimoda Y; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
Cancer Med; 2023 Jun; 12(11):12388-12401. PubMed ID: 37062059
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.
Xu Z; Hao X; Yang K; Wang Q; Wang J; Lin L; Teng F; Li J; Xing P
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3081-3089. PubMed ID: 34982222
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Yamaguchi O; Imai H; Minemura H; Suzuki K; Wasamoto S; Umeda Y; Osaki T; Kasahara N; Uchino J; Sugiyama T; Ishihara S; Ishii H; Naruse I; Mori K; Kotake M; Kanazawa K; Minato K; Kagamu H; Kaira K
Cancer Chemother Pharmacol; 2020 Apr; 85(4):761-771. PubMed ID: 32193618
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study.
Yang J; Zeng R; Zhou J; Luo L; Lyu M; Liu F; Sun X; Zhou L; Wang X; Bao Z; Chen W; Dumoulin DW; Gao B; Xiang Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1038-1050. PubMed ID: 35832441
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer.
Xu M; Hao Y; Shi Z; Song Z
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17987-17995. PubMed ID: 37975902
[TBL] [Abstract][Full Text] [Related]
10. Eosinophil and IFN-γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy.
Hu WT; Zhang Q; Zhang Z; He X; Zhou M; Guo Y; Wang X
Front Immunol; 2023; 14():1112409. PubMed ID: 36949952
[TBL] [Abstract][Full Text] [Related]
11. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study.
Yan X; Zhao L; Wu F; Shen B; Zhou G; Feng J; Yue C; Zhu J; Yu S
J Thorac Dis; 2024 Mar; 16(3):1787-1803. PubMed ID: 38617775
[TBL] [Abstract][Full Text] [Related]
13. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
[TBL] [Abstract][Full Text] [Related]
14. Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data.
Nakahama K; Izumi M; Yoshimoto N; Fukui M; Sugimoto A; Nagamine H; Ogawa K; Sawa K; Tani Y; Kaneda H; Mitsuoka S; Watanabe T; Asai K; Kawaguchi T
Anticancer Res; 2023 May; 43(5):2185-2197. PubMed ID: 37097681
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
Rousseau A; Tagliamento M; Auclin E; Aldea M; Frelaut M; Levy A; Benitez JC; Naltet C; Lavaud P; Botticella A; Grecea M; Chaput N; Barlesi F; Planchard D; Besse B
Eur J Cancer; 2023 Mar; 182():107-114. PubMed ID: 36758475
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: A systematic review and meta-analysis.
Feng Y; Tao Y; Chen H; Zhou Y; Tang L; Liu C; Hu X; Shi Y
Thorac Cancer; 2023 Sep; 14(25):2536-2547. PubMed ID: 37551891
[TBL] [Abstract][Full Text] [Related]
19. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
Kim H; Kim DW; Kim M; Lee Y; Ahn HK; Cho JH; Kim IH; Lee YG; Shin SH; Park SE; Jung J; Kang EJ; Ahn MJ
Cancer; 2022 Feb; 128(4):778-787. PubMed ID: 34705268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]